CLDN18 (Claudin 18)

News alerts, weekly reports and conference planners

Entrez ID:

51208

Related tests:

‹

VENTANA CLDN18 (43-14A) Assay (2)

Claudin18.2 IHC 14G11 pharmDx

VENTANA CLDN18 (43-14A) Assay (2)

Claudin18.2 IHC 14G11 pharmDx

›

CLDN18.2 positive + HER-2 negative	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 positive + HER-2 negative	Gastroesophageal Junction Adenocarcinoma	zolbetuximab-clzb Sensitive: A1 - Approval zolbetuximab-clzb Sensitive : A1	zolbetuximab-clzb Sensitive: A1 - Approval zolbetuximab-clzb Sensitive : A1
CLDN18.2 positive + HER-2 negative	Gastric Cancer	CLDN18.2 positive + HER-2 negative	Gastric Cancer	zolbetuximab-clzb Sensitive: A1 - Approval zolbetuximab-clzb Sensitive : A1	zolbetuximab-clzb Sensitive: A1 - Approval zolbetuximab-clzb Sensitive : A1
CLDN18.2 expression + HER-2 negative	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 expression + HER-2 negative	Gastroesophageal Junction Adenocarcinoma	zolbetuximab-clzb Sensitive: B - Late Trials zolbetuximab-clzb Sensitive : B	zolbetuximab-clzb Sensitive: B - Late Trials zolbetuximab-clzb Sensitive : B
CLDN18.2 expression + HER-2 negative	Gastric Cancer	CLDN18.2 expression + HER-2 negative	Gastric Cancer	zolbetuximab-clzb Sensitive: B - Late Trials zolbetuximab-clzb Sensitive : B	zolbetuximab-clzb Sensitive: B - Late Trials zolbetuximab-clzb Sensitive : B
CLDN18.2 expression	Gastric Cancer	CLDN18.2 expression	Gastric Cancer	EO-3021 Sensitive: B - Late Trials EO-3021 Sensitive : B	EO-3021 Sensitive: B - Late Trials EO-3021 Sensitive : B
CLDN18.2 positive	Gastric Cancer	CLDN18.2 positive	Gastric Cancer	IBI-343 Sensitive: B - Late Trials IBI-343 Sensitive : B	IBI-343 Sensitive: B - Late Trials IBI-343 Sensitive : B
CLDN18.2 expression	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 expression	Gastroesophageal Junction Adenocarcinoma	EO-3021 Sensitive: B - Late Trials EO-3021 Sensitive : B	EO-3021 Sensitive: B - Late Trials EO-3021 Sensitive : B
CLDN18.2 expression	Esophageal Adenocarcinoma	CLDN18.2 expression	Esophageal Adenocarcinoma	zolbetuximab-clzb Sensitive: C2 – Inclusion Criteria zolbetuximab-clzb Sensitive : C2	zolbetuximab-clzb Sensitive: C2 – Inclusion Criteria zolbetuximab-clzb Sensitive : C2
CLDN18.2 expression	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 expression	Gastroesophageal Junction Adenocarcinoma	zolbetuximab-clzb Sensitive: C2 – Inclusion Criteria zolbetuximab-clzb Sensitive : C2	zolbetuximab-clzb Sensitive: C2 – Inclusion Criteria zolbetuximab-clzb Sensitive : C2
CLDN18.2 expression	Gastric Adenocarcinoma	CLDN18.2 expression	Gastric Adenocarcinoma	zolbetuximab-clzb Sensitive: C2 – Inclusion Criteria zolbetuximab-clzb Sensitive : C2	zolbetuximab-clzb Sensitive: C2 – Inclusion Criteria zolbetuximab-clzb Sensitive : C2
CLDN18.2 positive	Gastric Cancer	CLDN18.2 positive	Gastric Cancer	CT041 Sensitive: C2 – Inclusion Criteria CT041 Sensitive : C2	CT041 Sensitive: C2 – Inclusion Criteria CT041 Sensitive : C2
CLDN18.2 positive	Pancreatic Ductal Adenocarcinoma	CLDN18.2 positive	Pancreatic Ductal Adenocarcinoma	CT041 Sensitive: C2 – Inclusion Criteria CT041 Sensitive : C2	CT041 Sensitive: C2 – Inclusion Criteria CT041 Sensitive : C2
CLDN18.2 positive	Solid Tumor	CLDN18.2 positive	Solid Tumor	MIL93 Sensitive: C2 – Inclusion Criteria MIL93 Sensitive : C2	MIL93 Sensitive: C2 – Inclusion Criteria MIL93 Sensitive : C2
CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma	CT041 Sensitive: C2 – Inclusion Criteria CT041 Sensitive : C2	CT041 Sensitive: C2 – Inclusion Criteria CT041 Sensitive : C2
CLDN18.2 positive	Gastric Cancer	CLDN18.2 positive	Gastric Cancer	AB011 Sensitive: C2 – Inclusion Criteria AB011 Sensitive : C2	AB011 Sensitive: C2 – Inclusion Criteria AB011 Sensitive : C2
CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma	AZD0901 Sensitive: C2 – Inclusion Criteria AZD0901 Sensitive : C2	AZD0901 Sensitive: C2 – Inclusion Criteria AZD0901 Sensitive : C2
CLDN18.2 positive	Gastric Cancer	CLDN18.2 positive	Gastric Cancer	AZD0901 Sensitive: C2 – Inclusion Criteria AZD0901 Sensitive : C2	AZD0901 Sensitive: C2 – Inclusion Criteria AZD0901 Sensitive : C2
CLDN18.2 expression	Pancreatic Cancer	CLDN18.2 expression	Pancreatic Cancer	SOT102 Sensitive: C2 – Inclusion Criteria SOT102 Sensitive : C2	SOT102 Sensitive: C2 – Inclusion Criteria SOT102 Sensitive : C2
CLDN18.2 expression	Gastric Cancer	CLDN18.2 expression	Gastric Cancer	SOT102 Sensitive: C2 – Inclusion Criteria SOT102 Sensitive : C2	SOT102 Sensitive: C2 – Inclusion Criteria SOT102 Sensitive : C2
CLDN18.2 expression	Pancreatic Cancer	CLDN18.2 expression	Pancreatic Cancer	ASP2138 Sensitive: C2 – Inclusion Criteria ASP2138 Sensitive : C2	ASP2138 Sensitive: C2 – Inclusion Criteria ASP2138 Sensitive : C2
CLDN18.2 expression	Gastric Cancer	CLDN18.2 expression	Gastric Cancer	ASP2138 Sensitive: C2 – Inclusion Criteria ASP2138 Sensitive : C2	ASP2138 Sensitive: C2 – Inclusion Criteria ASP2138 Sensitive : C2
CLDN18.2 expression	Pancreatic Cancer	CLDN18.2 expression	Pancreatic Cancer	EO-3021 Sensitive: C2 – Inclusion Criteria EO-3021 Sensitive : C2	EO-3021 Sensitive: C2 – Inclusion Criteria EO-3021 Sensitive : C2
CLDN18.2 expression	Solid Tumor	CLDN18.2 expression	Solid Tumor	EO-3021 Sensitive: C2 – Inclusion Criteria EO-3021 Sensitive : C2	EO-3021 Sensitive: C2 – Inclusion Criteria EO-3021 Sensitive : C2
CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 positive	Gastroesophageal Junction Adenocarcinoma	zolbetuximab-clzb Sensitive: C2 – Inclusion Criteria zolbetuximab-clzb Sensitive : C2	zolbetuximab-clzb Sensitive: C2 – Inclusion Criteria zolbetuximab-clzb Sensitive : C2
CLDN18.2 expression	Lung Cancer	CLDN18.2 expression	Lung Cancer	EO-3021 Sensitive: C2 – Inclusion Criteria EO-3021 Sensitive : C2	EO-3021 Sensitive: C2 – Inclusion Criteria EO-3021 Sensitive : C2
CLDN18.2 expression	Esophageal Cancer	CLDN18.2 expression	Esophageal Cancer	AZD5863 Sensitive: C2 – Inclusion Criteria AZD5863 Sensitive : C2	AZD5863 Sensitive: C2 – Inclusion Criteria AZD5863 Sensitive : C2
CLDN18.2 expression	Pancreatic Cancer	CLDN18.2 expression	Pancreatic Cancer	AZD5863 Sensitive: C2 – Inclusion Criteria AZD5863 Sensitive : C2	AZD5863 Sensitive: C2 – Inclusion Criteria AZD5863 Sensitive : C2
CLDN18.2 expression	Gastric Cancer	CLDN18.2 expression	Gastric Cancer	AZD5863 Sensitive: C2 – Inclusion Criteria AZD5863 Sensitive : C2	AZD5863 Sensitive: C2 – Inclusion Criteria AZD5863 Sensitive : C2
CLDN18.2 overexpression	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 overexpression	Gastroesophageal Junction Adenocarcinoma	zolbetuximab-clzb Sensitive: C3 – Early Trials zolbetuximab-clzb Sensitive : C3	zolbetuximab-clzb Sensitive: C3 – Early Trials zolbetuximab-clzb Sensitive : C3
CLDN18.2 overexpression	Gastric Cancer	CLDN18.2 overexpression	Gastric Cancer	zolbetuximab-clzb Sensitive: C3 – Early Trials zolbetuximab-clzb Sensitive : C3	zolbetuximab-clzb Sensitive: C3 – Early Trials zolbetuximab-clzb Sensitive : C3
CLDN18-ARHGAP fusion	Gastric Cancer	CLDN18-ARHGAP fusion	Gastric Cancer	CLDN18.2-targeted antibody-drug conjugate Sensitive: C3 – Early Trials CLDN18.2-targeted antibody-drug conjugate Sensitive : C3	CLDN18.2-targeted antibody-drug conjugate Sensitive: C3 – Early Trials CLDN18.2-targeted antibody-drug conjugate Sensitive : C3
CLDN18.2 expression	Gastric Cancer	CLDN18.2 expression	Gastric Cancer	Q-1802 Sensitive: C3 – Early Trials Q-1802 Sensitive : C3	Q-1802 Sensitive: C3 – Early Trials Q-1802 Sensitive : C3

CLDN18 (Claudin 18)

Associations(60)

Associations
(60)